Table 2 Summary of preclinical prophylactic prostate cancer tumour challenge studies utilising DNA vaccines

PSCA/STEAP: pCI-neo-mPSCA and/or pCI-neo-mSTEAP1 (100 μg) prime plus MVA-mPSCA and/or MVA-mSTEAP1 (1X10⁷ pfu) boost

C57 BL/6

i.m. prime

Significant reduction in tumour volume

[17]

TRAMP C-1

i.p. boost

Significant delay in time to form tumours

hPSA: phPSA (50 μg) with or without CpG

C57 BL/6

i.m. with EP

Significant delay in appearance of tumours

[46]

TRAMP C-1/hPSA

Significantly prolonged survival

PSMA/PSCA/STEAP: rAd/PSMA, rAD/PSCA, rAd/STEAP prime (1X10⁸ PFU); TRAMP C-1 pulsed DCs (2X10⁶ cells) boost

C57 BL/6

i.v. prime

Tumour Growth Significantly delayed

[112]

TRAMP C-1

s.c. boost

STEAP: mSTEAP DN A (2 μg) prime with: mSTEAP DN A (2 μg) or mSTEAP-VRP (10⁶ IU) boost; or mSTEAP-VRP (10⁶ IU) prime and boost

C57 BL/6

i.d. (gene gun)

Significantly prolonged survival

[56]

TRAMP C-2

s.c.

Significantly delayed tumour growth